NEW YORK, Aug. 26, 2016 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Emergent BioSolutions Inc. (NYSE: EBS).
On June 22, 2016, Emergent revealed that the U.S. government had issued two official solicitation notices specifying that it would only be purchasing 29.4 million doses of the BioThrax vaccine from Emergent, roughly one-third less than the 44.75 million doses in Emergent's first agreement with the U.S. government. In response to this news, Emergent stock dropped roughly $8.00 per share to close at $31.33 on June 22, 2016.
If you are a shareholder of Emergent and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at:
You may also contact Robert H. Lefkowitz, Esq. either via email at [email protected] or by telephone at 212-725-1000. One of our attorneys will personally speak with you about the case at no cost or obligation.
Purcell Julie & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct. For more information about the firm and its attorneys, please visit http://pjlfirm.com. Attorney advertising. Prior results do not guarantee a similar outcome.
SOURCE Purcell Julie & Lefkowitz LLP